Diagenic Presents Test Data for Parkinson Disease at European IPA Meeting
News May 11, 2006
DiaGenic ASA has announced that it had presented a poster on discriminatory assays for Parkinson and Alzheimer’s diseases at the European Regional Meeting of the International Psychogeriatric Association in Lisbon.
The study employed a peripheral blood-based assay with a specific Alzheimer’s gene expression signature developed using DiaGenic’s patented method.
Researchers found that 19 out of 20 Parkinson-diagnosed patients could be discriminated from Alzheimer’s sufferers. Furthermore, a specific gene expression signature for Parkinson was also identified.
The study is part of a larger follow-on study validating DiaGenic’s Alzheimer’s gene expression assay on an ABI microarray platform, the results of which will be presented at the ICAD in Madrid in July.
"These findings showing that our blood-based gene expression assay approach can also be applied to Parkinson disease is extremely encouraging," said Anders Lonneborg, CEO, DiaGenic ASA.
"Alzheimer’s and Parkinson have different underlying pathologies, but overlapping clinical profiles as many PD patients will also develop dementia."
"Our goal is develop simple blood-based tests that will enable physicians to discriminate between patients at an early stage, since an increasing number of studies show that early therapeutic intervention can make a significant difference in improving quality of life."
Single Gene Change in Gut Bacteria Alters Host MetabolismNews
Scientists have found that deleting a single gene in a particular strain of gut bacteria causes changes in metabolism and reduced weight gain in mice. The research provides an important step towards understanding how the microbiome – the bacteria that live in our body – affects metabolism.READ MORE
Gotta Sample 'Em All! Underwater Pokéball Captures Ocean LifeNews
A new device developed by Wyss Institute reseachers safely traps delicate sea creatures inside a folding polyhedral enclosure and lets them go without harm using a novel, origami-inspired design. The ultimate aim is to allow the sea creatures to be (gently) analyzed in high detail.READ MORE
CRISPR Screening Reveals Sickle Cell Disease TargetNews
A key signaling protein, known as heme-regulated inhibitor (HRI), has been identified as a potential therapeutic target for the development of drugs to treat sickle cell disease, using a CRISPR screening approach.READ MORE
International Conference on Neurooncology and Neurosurgery
Sep 17 - Sep 18, 2018